They’re not linear, and they’re not steps in a process.
over the lifetime of a portfolio of products.and where there appears to be little impact..
It is also worth saying that the results have not been modelled where there are lower risk profiles than those of bringing new pharmaceutical products to market.. Let me start with a first curve.. M. odelled.a scenario where the revenue value of the new products was very high.you can see that scale has little relative influence over the NPV at different scales.
There is a difference, smaller scale has a lower return and somewhere the scale can be optimised, but changes are relatively small and would suggest that sticking with an installed or familiar scale may make sense, if you are confident that most of your products will be blockbusters..There is a natural upper limit to the.
and this maybe should be understood to prevent “traffic-jam” consequences..
at low value products, scale appears to be.Spans can be specific to particular clients, but to the operative on site, it's the same yellow bracket, requiring the same torque wrench and two bolts.
Platforms enable us to get down to a much more granular level and simultaneously open the door for continual improvement and variability going forward with respect to supply chain choices, material choices and so on.. Maximising value with construction platforms.Because platform construction uses a limited number of components, it gives us a greater amount of control.
We’re able to limit the number of processes and operations which have to happen on site and we can control materials much more accurately.There are also considerable time-saving benefits with P-DfMA, which enable us to spend more time on the design and optimisation of components in the first place.